By Mill Chart
Last update: Feb 21, 2024
Unearth the potential of JOHNSON & JOHNSON (NYSE:JNJ) as a dividend stock recommended by our stock screening tool. NYSE:JNJ maintains a robust financial footing and delivers a sustainable dividend. We'll delve into the details below.
ChartMill assigns a proprietary Dividend Rating to each stock. The score is computed by evaluating various valuation aspects, like the yield, the history, the dividend growth and sustainability. NYSE:JNJ was assigned a score of 7 for dividend:
A critical element of ChartMill's stock evaluation is the Health Rating, which spans from 0 to 10. This rating considers multiple health factors, including liquidity and solvency, both in absolute terms and relative to industry peers. NYSE:JNJ has received a 6 out of 10:
ChartMill's Profitability Rating offers a unique perspective on stock analysis, providing scores from 0 to 10. These ratings consider a wide range of profitability metrics and margins, both in comparison to industry peers and on their own merits. For NYSE:JNJ, the assigned 7 is a significant indicator of profitability:
More Best Dividend stocks can be found in our Best Dividend screener.
Our latest full fundamental report of JNJ contains the most current fundamental analsysis.
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
JOHNSON & JOHNSON
NYSE:JNJ (4/19/2024, 4:57:49 PM)
After market: 147.9 -0.01 (-0.01%)147.91
+2.17 (+1.49%)
Small-cap stocks have been the market laggards but these standouts showed how to beat even top-tier tech names at their own game.
The Nasdaq and S&P 500 tumbled below their 50-day lines.
This is what could happen next to Johnson & Johnson shares.
NVIDIA, Alphabet, Johnson & Johnson, Broadridge Financial and Textron are included in this Analyst Blog.
A Florida jury on Thursday concluded that Johnson & Johnson's baby powder talc product did not cause the ovarian cancer of a Florida woman who died in 2019. The lawsuit was brought by family members of Patricia Matthey, a Sarasota County resident who used Johnson's baby powder daily from 1965 until August 2016, when she was diagnosed with ovarian cancer, according to her family's lawsuit. J&J's Worldwide Vice President of Litigation Erik Haas said the company was vindicated by the jury's decision.
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Alphabet Inc. (GOOGL) and Johnson & Johnson (JNJ).
Discover recession-proof stocks that thrive amid economic uncertainty, offering stability and consistent growth.
Investors wondering which tax refund stocks to invest in should consider these names, each of which is a capital compounder.
Although monetary policy seemed to be moving in a dovish direction, a pivot may warrant a look at stocks for Fed hikes.
Top S&P500 movers in Thursday's after hours session
Balancing Dividends and Fundamentals: The Case of JOHNSON & JOHNSON (NYSE:JNJ).